Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads tumor slides to match cancer patients with trials

NCT ID NCT07814872

Diagnosis Sponsor: Harvard Medical School (HMS and HSDM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Many cancer trials require patients to have specific molecular markers, so researchers test large numbers of people to find the few who qualify. This study evaluates FATHOM, an AI system that reads clinical trial records and routine tumor slides to predict which patients carry those markers. Researchers preregister the rules, then apply the AI-generated policies to archived slides and compare predictions with existing molecular results. The study analyzes images and records only and does not enroll or contact patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FATHOM, an AI system that reads tumor slides and clinical trial records to prioritize patients for molecular testing
What this could lead to
If it works, this approach could help cancer patients find matching clinical trials faster and spare some people unnecessary molecular testing.
What could go wrong
The AI policies are tested on archived slides and records, not real-time patient care, so performance in routine practice may differ. Some markers may be too hard to predict from images alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient records from archived, multi-institutional cohorts of patients with histologically confirmed cancers, relevant molecular profiling results, and at least one diagnostic hematoxylin and eosin (H\&E) whole-slide image. For the evaluation of a given policy, patients whose slides were used to train that policy's classifier are excluded. No patients are enrolled or contacted; enrollment counts refer to patient records analyzed.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a histologically confirmed cancer * Availability of relevant molecular profiling results * At least one diagnostic hematoxylin and eosin (H\&E) whole-slide image Exclusion Criteria: * Poor-quality or unreadable slides, assessed independently of model output * Patients whose slides were used to train a policy's classifier, for that policy's evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm colorectal neoplasm endometrial cancer endometrium neoplasm gastric neoplasm glioma head and neck neoplasm Head and Neck Neoplasms kidney cancer kidney neoplasm lung neoplasm neoplasm ovarian cancer ovarian neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms Colorectal neoplasms Endometrial neoplasms GLIOMA Head and neck neoplasms Kidney neoplasms Lung neoplasms Neoplasms (cancer / tumors) Ovarian neoplasms Pancreatic neoplasms Stomach neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Harvard Medical School

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.